KRAS and colorectal carcinoma: Imperiale et al. detected multiple stool DNA targets (KRAS mutations, aberrant NDRG4 and BMP3 methylations) and used logistic-regression algorithm to build model for screening CRC [92], the combination of the stool DNA targets had a sensitivity of 92.3% for CRC and 42.6% for advanced adenomas, suggesting that multi-targeted fecal DNA screening may be an alternative test for patients who are intolerant to colonoscopy.